Compass Therapeutics, Inc. (CMPX) dividends
CMPX on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Compass Therapeutics, Inc. dividend: key facts
Own Compass Therapeutics, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next CMPX dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Results, reports and dividend announcements
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Compass Therapeutics reports Q3 EPS (15c), consensus (13c)9 Nov 2026 · TheFly
âThe third quarter was a period of sustained execution across our pipeline,â said Thomas Schuetz, Chief Executive Officer and Vice Chairman of the Board of Directors. âWe continue to prepareâ¦
- Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update9 Nov 2026 · GlobeNewsWire
Compass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA. Data from the COMPANION-002 study of tovecimig, including newly disc...
- Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting6 Nov 2026 · GlobeNewsWire
CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized b...
- Compass Therapeutics to Participate in Upcoming November Investor Events2 Nov 2026 · GlobeNewsWire
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
- Compass announces publication of Phase 2/3 COMPANION-002 study26 Oct 2026 · TheFly
Compass Therapeutics (CMPX) announced the publication of results from the positive Phase 2/3 COMPANION-002 study of tovecimig in combination with paclitaxel in patients with previously treated, advanc...
- Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 202624 Oct 2026 · GlobeNewsWire
BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
- Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)17 Oct 2026 · GlobeNewsWire
BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
- Wedbush downgrades Compass Therapeutics as FDA throws wrench at tovecimig26 Sep 2026 · TheFly
As previously reported, Wedbush downgraded Compass Therapeutics (CMPX) to Neutral from Outperform with a price target of $1, down from $5. The firm notes the company announced that the FDAâ¦
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.